Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
NCT ID: NCT04543006
Last Updated: 2020-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
170 participants
INTERVENTIONAL
2020-09-08
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will explore patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.
The investigators will determine whether this persistance varies according to
* the severity of the Covid-19
* a treatment by steroids during the covid-19. This will help to anticipate whether a second wave of infection is possible in a non-naive population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neutralizing Antibody Level After COVID-19 Vaccination
NCT05083026
Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms
NCT05484700
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
NCT04469634
COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB)
NCT04416308
Antibodies Responses to COVID-19 Infection in Hospitalized Patients
NCT04520880
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will explore adult patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.
The investigators will determine whether this persistance varies according to
* the severity of the Covid-19 (3 groups: no oxyegn therapy; oxygen therapy of less than 3L/min; oxygen therapy of 3L/min or more)
* a treatment by steroids during the covid-19. Immunocompromised patients will be excluded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Covid-19
only arm: Covid-19 proven by PCR
serology
blood sample of 10 ml twice (6 and 12 months after the Covid-19)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
serology
blood sample of 10 ml twice (6 and 12 months after the Covid-19)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* immunocompromised at the onset of Covid-19
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olivier Epaulard, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Grenoble
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EssaiClinique_PANCOLIN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.